RECRUITING

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

Description

This trial evaluates the treatment response of colorectal cancer that has spread to the liver (liver metastases) using intravoxel incoherent motion diffusion weighted imaging (IVIM DWI). IVIM DWI is new kind of imaging scan that may help measure changes in disease before and after chemotherapy in patients with colorectal liver metastases.

Conditions

Metastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the LiverResectable Colorectal CarcinomaStage IV Colorectal Cancer AJCC V8Stage IVA Colorectal Cancer AJCC V8Stage IVB Colorectal Cancer AJCC V8Stage IVC Colorectal Cancer AJCC V8
Talk to us

Related Conditions:

Metastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the LiverResectable Colorectal CarcinomaStage IV Colorectal Cancer AJCC V8Stage IVA Colorectal Cancer AJCC V8Stage IVB Colorectal Cancer AJCC V8Stage IVC Colorectal Cancer AJCC V8

Study Overview

On this page

Study Details

Study overview

This trial evaluates the treatment response of colorectal cancer that has spread to the liver (liver metastases) using intravoxel incoherent motion diffusion weighted imaging (IVIM DWI). IVIM DWI is new kind of imaging scan that may help measure changes in disease before and after chemotherapy in patients with colorectal liver metastases.

Evaluation of Treatment Response of Colorectal Cancer Liver Metastases with Intravoxel Incoherent Motion Diffusion Weighted Imaging

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

Condition
Metastatic Colorectal Carcinoma
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with treatment-naive resectable CLM, who will start chemotherapy with oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with 5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent
  • * Patients with at least 1 colorectal liver metastasis measuring at least 1 cm
  • * Patients with anticipated follow-up before and after surgery at MD Anderson
  • * Patients who have already received preoperative chemotherapy for the CLM or will undergo radiation therapy, ablative therapies, or other non-surgical therapies directed at the liver
  • * Patients allergic to gadolinium
  • * Patients with pacemakers
  • * Greater than 400 pounds in weight

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Priya R Bhosale, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2026-01-31